

GPTHEALTH/CS/SE/2024-25

May 21, 2024

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
--	---

Dear Sir/Madam

Subject: Subject: Outcome of Board Meeting held on Tuesday, May 21, 2024:

In continuation of our letter dated May 14, 2024, intimating the date of Board meeting, and in pursuance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We would like to inform you that, the Board Meeting of the Company was held today i.e. on Tuesday, May 21, 2024 at the registered office of the Company where, the Board has considered and approved the following matters amongst others:

1. Approved the Audited Financial Results (Standalone) as per IND-AS along with Auditors Report thereon for the 4th Quarter and year ended March 31, 2024 is enclosed as annexure to this outcome;
2. Declaration of unmodified opinion by statutory auditors in their Auditors Report on the annual audited standalone financial results for the quarter and year ended March 31, 2024, a declaration as required in accordance with Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed as annexure to this outcome;
3. Approved convening of 35th Annual General Meeting on Thursday, July 25, 2024 through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The deemed venue for the 35th AGM shall be the Registered Office of the Company;
4. Recommended Final Dividend of 15% i.e. Rs. 1.5 per equity share on the face value of Rs. 10 each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the ensuing 35th Annual General Meeting of the Company. The dividend, if approved by the members, will be paid within the stipulated timeliness;
5. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Friday, July 19, 2024 to Thursday, July 25, 2024 (both days inclusive) for the purpose of 35th Annual General Meeting and Dividend for the financial year 2023-24. The record (cut off) date is Thursday, July 18, 2024;
6. Approved the appointment of S R Batliboi & Co LLP, Chartered Accountants (Firm Registration No. 301003E/E300005) as Statutory Auditors of the Company in place of Singhi & Co, Chartered Accountants (Firm Registration No. 302049E), the retiring Statutory Auditor, to hold office for a period of 5(five) consecutive years from the conclusion of ensuing 35th Annual General Meeting till the Conclusion of 40th Annual General Meeting of our Company to be held in the year 2029, subject to the approval of the shareholders of the Company;



7. Approved the reappointment of Mr. Ashok Kumar Daga as the Secretarial Auditors of the Company for FY 2024-25;
8. Approved the reappointment of S.K. Sahu & Associates as the Cost Auditors of the Company for FY 2024-25, subject to ratification of their remuneration of the shareholders of the Company;
9. Approved the reappointment of Sumit Binani & Associates, Chartered Accountants and ARVS & Associates, Chartered Accountants, as Internal Auditors of the Company for the FY 2024-25;
10. Approved reappointment of the following Directors, based on the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders in the ensuing 35th Annual General Meeting of the Company;
 - a. Mr. Dwarika Prasad Tantia (DIN:00001341) as Chairman and Whole Time Director for further period of three (3) consecutive years w.e.f. October 1, 2024;
 - b. Mr. Anurag Tantia (DIN03118844) as Whole Time Director designated as the Executive Director for further period of three (3) consecutive years w.e.f. October 1, 2024.
11. In pursuance of Regulation 17(6)(ca) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") approved payment of Doctor Consultancy Fees to Dr. Ghanshyam Goyal, Non-Executive Non Independent Director of the Company for FY 2024-25 based on the recommendation of the Nomination and Remuneration Committee subject to approval of shareholders in the ensuing 35th Annual General Meeting of the Company;
12. Approved revision in remuneration payable to Mrs. Kriti Tantia, Chief Financial Officer, a relative of Mr. Dwarika Prasad Tantia, Chairman of the Company, for holding an office or place of profit in the Company pursuant to the provisions of Section 188 (1) (f) of the Companies Act, 2013 based on the recommendation of the Audit and Nomination and Remuneration Committee subject to approval of shareholders in the ensuing 35th Annual General Meeting of the Company;

A copy of aforesaid financial result along with Auditors Report and declaration of unmodified opinion as per Regulation 33 of SEBI (LODR) Regulations, 2015 is enclosed herewith for your record and reference. The said results will be uploaded on the website of the company at www.ilshospitals.com.


The said results will be duly published in the newspaper as required by Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and will also be uploaded on the website of the company at www.ilshospitals.com.

The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 for the relevant outcome is enclosed as Annexure -'A'.

The Board Meeting commenced at 2:30 P.M. and concluded at 3.00 P.M.

We request you to kindly take the same on records. This is for your information and records.

For GPT Healthcare Limited


Ankur Sharma
Company Secretary and Compliance Officer
M.No A31833



Encl: A/a

Disclosure under Regulation 30 of SEBI (LODR), Regulations, 2015

Sl. No	Particulars	S R Batliboi & Co LLP, Chartered Accountants	Mr. Ashok Kumar Daga, Practicing Company Secretary	S.K. Sahu & Associates, Cost Accountants	Sumit Binani & Associates, Chartered Accountants and ARVS & Associates, Chartered Accountants
1	Reason for change viz. appointment, resignation, removal, death or otherwise.	Appointment of S R Batliboi & Co LLP as Statutory Auditor of the Company for a term of five (5) consecutive years in place of M/s. Singhi & Co, Chartered Accountants, the retiring Statutory Auditor, subject to approval of shareholders in the ensuing 35 th Annual General Meeting of the Company.	Mr. Ashok Kumar Daga, Practicing Company Secretary reappointed as Secretarial Auditor of the Company for the financial year 2024-25.	S.K. Sahu & Associates, Cost Accountants reappointed as Cost Auditor of the Company for the financial year 2024-25, subject to ratification of their remuneration of the shareholders of the Company.	Sumit Binani & Associates, Chartered Accountants and ARVS & Associates, Chartered Accountants reappointed as Internal Auditors of the Company for the financial year 2024-25.
2	Date of appointment/cessation (as applicable) & term of appointment.	Appointment of S R Batliboi & Co LLP, Chartered Accountants (Firm Registration No. 301003E/ E300005) as Statutory Auditor of the Company for a period of 5 (five) years from the conclusion of the ensuing 35 th Annual General Meeting scheduled to be held in the year 2024 till the conclusion of the 40 th AGM to be held in the year 2029, subject to the approval of the shareholders of the Company.	Reappointed as Secretarial Auditors of the Company in the Board Meeting dated May 21, 2024 for the Financial year 2024-25.	Reappointed as Cost Auditor of the Company in the Board Meeting dated May 21, 2024 for the Financial year 2024-25.	Sumit Binani & Associates, Chartered Accountants and ARVS & Associates, Chartered Accountants reappointed as Internal Auditors of the Company in the Board Meeting dated May 21, 2024 for the Financial year 2024-25 for the financial year 2024-25.
3	Brief profile (in case of appointment)	S. R. Batliboi & Co. LLP ("the Firm") is limited liability partnership firm incorporated in India and is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India ("ICAI") with (ICAI Firm Registration No. 301003E/E300005). The Firm is part of S. R. Batliboi & Affiliates, a network of firms registered with the ICAI. The Firm was established in 1949 with its registered office in Kolkata and has offices across key cities in India. The Firm has a valid Peer Review certificate. All the network firms including the Firm are primarily engaged in providing audit and assurance services, certain tax and financial accounting advisory services to its clients.	Mr. Ashok Kumar Daga, a Practicing Company Secretary (Certificate of Practice Number 2948) is having more than 20 years of experience in the field of company secretarial matter.	M/s. S.K. Sahu & Associates, Cost Accountants, Membership No.28234 is having 15 years of Experience in the field of Cost Audit Matter.	a. Sumit Binani & Associates, Chartered Accountants was established in the year 2014 at Kolkata with a vision to deliver quality services. The firm's registration number with ICAI is FRN 325718E. Presently, the firm operates out of different locations at Kolkata with its associates from all across the Country. The firm offers multi-disciplinary services through its experienced team under the guidance of its dedicated partners. b. ARVS & Associates, Chartered Accountants is engaged in the activities in the line of Audit (Statutory, Internal & Tax), Direct & Indirect Taxation, related to the profession. The Firm has is a peer reviewed firm and the partners having experience of 15 years.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable	Not Applicable	Not Applicable	Not Applicable
5	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Not Applicable	Not Applicable	Not Applicable	Not Applicable



Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015 pertaining to appointment/ reappointment of Directors

Sl. No	Particulars	Mr. Dwarika Prasad Tantia	Mr. Anurag Tantia
		Chairman and Whole Time Director DIN: 00001341	Whole Time Director designated as Executive Director DIN:03118844
1	Reason for change viz. appointment	Re-appointment	Re-appointment
2	Date of appointment/cessation (as applicable) & term of appointment.	w.e.f. October 1, 2024 for 3 years till September 30, 2027, subject to approval of shareholders in the ensuing 35th Annual General Meeting of the Company.	w.e.f. October 1, 2024 for 3 years till September 30, 2027, subject to approval of shareholders in the ensuing 35th Annual General Meeting of the Company.
3	Brief profile (in case of appointment)	Dwarika Prasad Tantia is the Chairman and Whole-time Director of our Company. He has been associated with our Company since January 10, 2005. He graduated from the University of Calcutta in 1974. He has over 41 years of experience in the infrastructure and healthcare industry. He is the founding member of ILS Hospitals and oversees international business development, project execution and new business ventures. He has been appointed as the Honorary Consul of the Republic of Ghana in Kolkata.	Anurag Tantia is the Whole-time Director of our Company. He has been associated with our Company since October 2, 2011. He holds a degree of Bachelor of Science in management with honours from the University of Illinois. He has more than 12 years of experience in healthcare management and looks after the day-to-day operations of our Company.
4	Disclosure of relationships between directors (in case of appointment of a director).	He is not related to any Director of the Company. However, he is the father in law of Mrs. Kriti Tantia, CFO of the Company.	Mr. Anurag Tantia is the son of Dr. Om Tantia, Managing Director and Dr. Aruna Tantia, Non-Executive Non-Independent Director of the Company.
5	Information as required Circular No. LIST/COMP/ 14/2018- 19 and NSE/CML/2018/24	Nomination and Remuneration Committee while considering the re-appointment of Mr. Dwarika Prasad Tantia as Chairman and Whole-Time Director of the Company have verified and confirmed from him that he is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mr. Dwarika Prasad Tantia, being appointed as Chairman and Whole-Time Director, is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.	Nomination and Remuneration Committee while considering the re-appointment of Mr. Anurag Tantia as Whole-Time Director designated as Executive Director of the Company have verified and confirmed from him that he is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mr. Anurag Tantia, being appointed as Whole-Time Director designated as Executive Director, is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.





GPT Healthcare Limited

Regd. Office : GPT Centre, JC - 25, Sector-III, Salt Lake, Kolkata-700 106, India CIN : L70101WB1989PLC047402
Tel : +91-33-4050-7000 Fax : +91-33-4050-7999 E-mail : info@gptgroup.co.in Visit us : www.gptgroup.co.in

GPTHEALTH/CS/SE/2024-25

May 21, 2024

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
--	---

Dear Sir/Madam

Subject: Declaration on Auditor's Report with unmodified opinion for the year ended on March 31, 2024 under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and vide Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, as amended, it is hereby declared that the Statutory Auditors of the Company, Singhi & Co, Chartered Accountants (Firm Registration No. 302049E) have issued the audit report with unmodified opinion on the Audited Financial Statements (Standalone) for the quarter and year ended March 31, 2024.

Kindly take the above information on record.

Thanking You,

Yours sincerely,

For GPT Healthcare Limited




Kriti Tania
Chief Financial Officer

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of GPT Healthcare Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the accompanying statement of annual financial results of **GPT Healthcare Limited** (hereinafter referred to as the 'Company') for the year ended March 31, 2024 and the statement of assets and liabilities and the statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and total comprehensive income and other financial information of the Company for the year ended March 31, 2024 and the statement of assets and liabilities and the statement of cash flows as at and for the year ended on that date.

Basis for opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the ICAI) together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Management and Board of directors' responsibilities for the financial results

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the statement of assets and liabilities and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements/ results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.
5. In preparing the financial results, the Board of Directors of the Company is responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's responsibilities for the audit of the financial results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- i. Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - ii. Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - iv. Evaluate the appropriateness and reasonableness of disclosures made by the Management and Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
 - v. Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - vi. Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
 - vii. Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.
9. Materiality is the magnitude of misstatements in the financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Results.



10. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matters

10. The figures for the quarter ended March 31, 2024 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended on March 31, 2024 / March 31, 2023 and the published year to date figures upto the end of the third quarter of the current and previous financial year respectively. Also, the figures up to the end of the third quarter of the current financial year had only been reviewed by us as required under the Listing Regulations and not audited. The figures for the nine months ended Dec-22 were certified by the management and was neither audited nor reviewed by us.

Our conclusion is not modified in respect of above matters.

12. The annual financial results dealt with by this report have been prepared for the express purpose of filing with stock exchanges. These results are based on the audited financial statements of the Company for the year ended March 31, 2024 on which we issued an unmodified audit opinion vide our report dated May 21, 2024.



For Singhi & Co.
Chartered Accountants
Firm Registration Number: 302049E

Navindra Kumar Surana

(Navindra Kumar Surana)
Partner

Membership Number 053518

UDIN: 24053816BKACDE1499

Place: Kolkata

Date: May 21, 2024

GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India
CIN : L70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

Rs. in lakhs (except per share data)

Particulars	Quarter Ended			Year ended	
	31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Unaudited)	31.03.2024 (Audited)	31.03.2023 (Audited)
1 INCOME					
(a) Revenue from operations	9,942.58	9,659.17	9,608.30	40,019.30	36,103.71
(b) Other income	159.21	117.82	233.19	529.14	569.36
Total Income	10,101.79	9,776.99	9,841.49	40,548.44	36,673.07
2 Expenses					
(a) Cost of materials consumed	2,078.82	1,969.56	2,030.89	8,296.24	7,586.34
(b) Employee benefits expense	1,699.75	1,726.21	1,494.61	6,893.47	6,203.79
(c) Finance costs	159.40	169.05	252.10	710.50	916.39
(d) Depreciation and amortisation expense	475.87	450.11	404.06	1,798.19	1,491.23
(e) Other expenses	3,846.52	3,863.31	3,724.78	16,045.70	14,878.38
Total Expenses	8,260.36	8,178.24	7,906.44	33,744.10	31,076.13
3 Profit/(Loss) Before Tax (1-2)	1,841.43	1,598.75	1,935.05	6,804.34	5,596.94
4 Tax expense					
(a) Current tax	320.00	282.00	550.00	1,189.00	975.00
(b) Deferred tax (including MAT Credit entitlement)	239.80	169.75	349.44	838.44	722.64
(c) Income tax for earlier year	-	-	-	-	(1.46)
Total Tax expenses	559.80	451.75	899.44	2,027.44	1,696.18
5 Profit for the period (3-4)	1,281.63	1,147.00	1,035.61	4,776.90	3,900.76
6 Other Comprehensive Income					
(a) Items that will not be reclassified to profit or loss					
(i) Remeasurement of defined benefit plan	42.53	(10.00)	(9.14)	2.26	18.93
(ii) Income tax relating to above	(12.40)	2.92	2.66	(0.66)	(5.52)
(b) Items that will be reclassified to profit or loss	-	-	-	-	-
Other Comprehensive Income for the period	30.13	(7.08)	(6.48)	1.60	13.41
7 Total Comprehensive Income for the period (5+6)	1,311.76	1,139.92	1,029.13	4,778.50	3,914.17
8 Paid up equity share capital (face value of ₹10 each)	8,205.48	7,990.43	7,990.43	8,205.48	7,990.43
9 Other Equity				13,643.55	8,545.82
10 Earnings per equity share (of ₹ 10 each) :					
Basic & Diluted (₹)	1.59	1.44	1.30	5.96	4.88
	Not annualized				



Statement of Assets and Liabilities

(₹ in lakhs)

Particulars	As at	
	March 31, 2024 (Audited)	March 31, 2023 (Audited)
A) ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	20,106.83	20,370.49
(b) Capital work-in-progress	639.97	260.84
(c) Intangibles Assets	84.69	39.16
(d) Right of Use Assets	2,213.71	2,375.74
(e) Financial Assets		
(i) Investments	1,916.92	516.73
(ii) Loans	5.29	7.90
(iii) Other Financial Assets	972.82	680.42
(f) Non Current Tax (Net)	528.94	215.93
(g) Deferred Tax Asset (Net)	-	-
(g) Other Non Current Assets	66.98	81.58
Total Non-Current Assets (A)	26,536.15	24,548.79
B) Current Assets		
(a) Inventories	815.49	892.08
(b) Financial Assets		
(i) Investments	1,118.05	827.58
(ii) Trade receivable	2,428.48	2,067.66
(iii) Cash and cash equivalents	169.32	659.93
(iv) Other bank balances (other than Note 15 above)	743.70	225.01
(v) Loans	1,121.75	2,331.69
(vi) Other Financial Assets	1,462.62	961.11
(c) Other Current Assets	156.29	161.91
Total Current Assets (B)	8,015.70	8,126.97
Total Assets (A+B)	34,551.85	32,675.76
C) EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	8,205.48	7,990.43
(b) Other Equity	13,643.55	8,545.82
Total Equity (C)	21,849.03	16,536.25
Liabilities		
D) Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	362.40	4,026.71
(ii) Lease Liabilities	1,534.94	1,648.62
(b) Deferred Tax Liabilities (Net)	1,195.95	356.85
(c) Provisions	754.52	724.20
(d) Other Non Current Liabilities	1,134.20	1,198.65
Total Non-current Liabilities (D)	4,982.01	7,955.03
E) Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	879.66	2,440.55
(ii) Lease Liabilities	277.32	119.74
(iii) Trade payables		
-Total outstanding dues of creditors to micro enterprises and small enterprises	291.93	61.67
-Total outstanding dues of creditors to other than micro enterprises and small enterprises	3,416.92	3,277.77
(iv) Other Financial Liabilities	1,479.58	1,022.94
(b) Provisions	643.35	439.96
(c) Other Current Liabilities	702.05	821.85
Total Current Liabilities (E)	7,720.81	8,184.48
Total Liabilities F = (D+E)	12,702.82	16,139.51
Total Equity & Liabilities (C+F)	34,551.85	32,675.76



Statement of Cash Flows

(₹ in lakhs)

Particulars	Year Ended	
	March 31, 2024 (Audited)	March 31, 2023 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	6,804.34	5,596.94
<u>Adjustment to reconcile profit before tax to net cash flows</u>		
(a) Depreciation and Amortisation	1,798.19	1,491.23
(b) Finance Costs	710.50	916.39
(c) Loss on Sale of Property, Plant and Equipment	20.30	(45.14)
(d) Profit on Sale of Investments	(9.54)	(4.99)
(e) Capital Work-in Progress written off	28.50	-
(f) Unspent liabilities written back	(52.43)	(76.06)
(g) Bad debts / Advances & Claims written off	171.54	-
(h) Provision for Doubtful Trade Receivables / (written back)	10.38	48.51
(i) Gain on retirement of Right of Use Assets	(38.58)	-
(j) Deferred Revenue on Government Grant	(64.45)	(64.45)
(k) Gain on Fair Valuation of investments measured at FVPTL	(19.42)	(12.87)
(l) Interest Income	(360.36)	(387.97)
Operating Profit before Working Capital Changes	8,998.97	7,461.59
<u>Changes in Working capital</u>		
(a) (Increase)/ decrease in Inventories	76.59	(163.62)
(b) (Increase)/ decrease in Trade Receivables	(542.74)	(773.58)
(c) (Increase)/ decrease in Other Financial Assets	(783.72)	118.05
(d) (Increase)/ decrease in Non-Financial Assets	2.20	1.82
(e) Increase/ (decrease) in Trade Payables	451.71	522.67
(f) Increase/ (decrease) in Other Financial Liabilities	67.37	35.23
(g) Increase/ (decrease) in Provisions	231.45	134.57
(h) Increase/ (decrease) in Non-financial liabilities	(119.80)	327.79
Cash Generated from Operations	8,382.03	7,664.52
Direct Taxes Paid	(1,502.00)	(1,028.97)
Net Cash from / (used in) Operating Activities (A)	6,880.03	6,635.55
B. CASH FLOW FROM INVESTING ACTIVITIES		
(a) Purchase of Investments	(3,076.71)	(831.43)
(b) Purchase of Property, Plant & Equipment	(1,937.50)	(983.13)
(c) Sale/ Disposal of Property, Plant & Equipment	15.13	146.12
(d) Sale of Investments	1,415.01	544.25
(e) Payment towards acquisition of ROU Assets	0.76	(11.52)
(f) (Investment)/ Redemption of Fixed Deposits (net)	(530.56)	(168.92)
(g) Loan Refund received from Body Corporates	1,202.13	1,535.00
(h) Interest Received	391.16	284.96
Net Cash from / (used in) Investing Activities (B)	(2,520.58)	515.33
C. CASH FLOW FROM FINANCING ACTIVITIES		
(a) Dividend and Tax paid thereon	(2,397.13)	(3,196.17)
(b) Interest Paid	(513.52)	(785.60)
(c) Proceeds from Long Term Borrowings (Bank, FI's and Others)	-	24.50
(d) Repayment of Long Term Borrowings (Bank, FI's and Other)	(5,277.26)	(3,002.51)
(e) Proceeds / (Repayment) of Short Term Borrowings from Banks (Net)	14.98	(135.21)
(f) Proceeds from issue of equity shares	4,000.00	-
(g) Transaction cost on issue of equity shares	(247.90)	-
(h) Repayment of Lease Liabilities	(429.23)	(222.76)
Net Cash from / (used in) Financing Activities (C)	(4,850.06)	(7,317.75)
Net increase/(decrease) in Cash & Cash Equivalent (A+B+C)	(490.61)	(166.87)
Cash & Cash Equivalents at the beginning of the year	659.93	826.80
Cash & Cash Equivalents at the end of the year	169.32	659.93



Notes:

- 1 The above audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 21, 2024. The said results have also been audited by the statutory auditors of the Company.
- 2 The above audited financial results are also available on the Company's website www.ilshospitals.com and also on the stock exchange websites (www.bseindia.com and www.nseindia.com).
- 3 GPT Healthcare Limited ("the Company") has completed Initial Public Offering (IPO) comprising of fresh issue of 21,50,537 equity shares and offer for sale from investor selling shareholder of 2,60,82,786 equity shares of face value ₹10 each at an issue price of ₹186 per share for cash consideration aggregating to ₹ 52,513.98 lakhs. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange w.e.f. February
- 4 The Company has received an amount of ₹ 4,000 lakhs as gross proceeds from fresh issue of Equity shares through the Initial Public Offering (IPO). After deducting of proportionate issue expenses of ₹ 247.9 Lakh, the issue proceeds have been utilized as per approval of the Board of Directors in their meeting held on October 14, 2023. There is no deviation of the objects of offer. The details of utilisation of funds are given below.

(Amount in Lakhs)

Objects of the offer	Amount as per Prospectus	Utilisation of Net IPO Proceeds upto March 31, 2024	Unutilised Net IPO Proceeds upto March 31, 2024
Repayment of Loan	3,000.00	3,000.00	-
General Corporate Purpose	752.10	752.10	-
Issue Expenses	247.90	247.90	-
Total	4,000.00	4,000.00	-

- 5 The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India.
- 6 The Board of Directors has recommended a final dividend of ₹ 1.50 per equity share of ₹ 10 each for the financial year ended March 31, 2024. The total dividend for the year FY 2023-2024 including the interim dividend shall be ₹ 3.50 per equity share i.e. 35% of face value. This payment of final dividend is subject to the approval of members of the Company at ensuing Annual General Meeting of the Company.
- 7 This statement is prepared as per Indian Accounting Standards (IND AS) notified under Section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 8 The figures for the quarter ended March 31, 2024 and the corresponding quarter ended in the previous year are the balancing figures between audited figures in respect of the full financial year ended on March 31, 2024 / March 31, 2023 and the published year to date figures upto the end of the third quarter of the current and previous financial year respectively. Also, the figures up to the end of the third quarter of the current financial year had only been reviewed by the auditors as required under the Listing Regulations and not audited. The figures for the nine months ended December 31, 2022 were certified by the management and were neither audited nor reviewed.
- 9 Previous periods / year figures have been regrouped / rearranged wherever considered necessary to confirm to the current periods / year classification

Place : Kolkata
Date : May 21, 2024



For and on behalf of the Board of Directors

Dwarika
Dwarika Prasad Tantia
Executive Chairman

DiN : 00091341

